Get the Daily Brief
Latest Biotech News
Rapport Therapeutics’ Seizure Drug Surges on Phase II Data
Rapport Therapeutics has reported highly promising Phase II clinical trial results for its experimental epilepsy drug RAP-219, designed to treat drug-resistant focal onset seizures. The open-label...
Lung Cancer Therapeutics: Mixed Phase III and Phase II Trial Updates
Recent data from the International Association for the Study of Lung Cancer highlight mixed outcomes for emerging lung cancer therapies. Summit Therapeutics’ PD-1/VEGF bispecific antibody...
Servier’s Acquisition of Fragile X Syndrome Candidate KER-0193 for $450M
Servier SA has agreed to acquire KER-0193, a novel oral small molecule modulator targeting BK channels for Fragile X Syndrome (FXS), from Kaerus Bioscience for up to $450 million. KER-0193...
Epigenic Therapeutics Raises $60M to Advance CRISPR Epigenetic Therapies
Epigenic Therapeutics Co. Ltd. has closed a $60 million Series B financing round to advance clinical development of gene therapy candidates: EPI-003 for chronic hepatitis B virus (HBV) and EPI-001...
AI Models Predict Long-Term Stability of Biotherapeutic Cell Lines
Researchers at Massachusetts Institute of Technology have developed the first publicly available artificial intelligence model predicting the long-term stability of Chinese Hamster Ovary (CHO)...
David Baltimore, Nobel Laureate and Molecular Biology Pioneer, Dies at 87
David Baltimore, Nobel Prize-winning molecular biologist renowned for his discovery of reverse transcriptase and groundbreaking contributions to cancer and viral research, died at age 87....
RedC Biotech Develops Lab-Grown Universal Blood Supply from Stem Cells
Israeli startup RedC Biotech is pioneering large-scale production of universal donor red blood cells cultivated from stem cells within bioreactors, aiming to alleviate chronic global blood...
Cancer Cells Exploit Alternative Metabolic Pathways to Sustain Growth
Van Andel Institute researchers have uncovered an alternative metabolic route in cancer cells, whereby β-hydroxybutyrate is converted into cytosolic acetyl-CoA, vital for lipid synthesis and cell...
Takeda and Alkermes Advance Narcolepsy Therapies with Promising Trial Data
Takeda Pharmaceutical and Alkermes have released encouraging clinical trial results for their orexin receptor 2-selective agonists targeting narcolepsy. Takeda’s phase 3 trials demonstrated that...
BioNTech and Bristol Myers Show Mid-Stage Success for Lung Cancer Bispecific
BioNTech and Bristol Myers Squibb unveiled promising Phase 2 data for pumitamig (BNT327), a bispecific antibody targeting PD-1 and VEGF, in extensive-stage small cell lung cancer (ES-SCLC). The...
Summit Therapeutics Ivonescimab Phase 3 Data Falls Short on Overall Survival
Summit Therapeutics’ Phase 3 Harmoni trial for ivonescimab, a PD-1 and VEGF bispecific antibody, showed statistical improvement in progression-free survival but failed to improve overall survival...
Rapport Therapeutics’ Seizure Drug RAP-219 Surges on Phase 2 Success
Rapport Therapeutics reported positive Phase 2 trial results for RAP-219, an AMPAR negative allosteric modulator targeting focal onset seizures. The open-label study demonstrated a 77.8% median...
Servier Acquires Fragile X Syndrome Drug Candidate for $450 Million
French pharma Servier agreed to acquire KER-0193, an oral small molecule modulator targeting BK channels for Fragile X syndrome, from UK biotech Kaerus Bioscience for up to $450 million. KER-0193...
Takeda and Alkermes Advance Narcolepsy Drugs with Positive Trial Data
Takeda Pharmaceutical and Alkermes each presented encouraging clinical trial data for their orexin receptor 2 (OX2R) selective agonists targeting narcolepsy, a debilitating sleep disorder....
David Baltimore, Nobel Laureate Molecular Biologist, Passes Away at 87
David Baltimore, a Nobel Prize-winning molecular biologist renowned for seminal contributions including the discovery of reverse transcriptase and pivotal insights into HIV and cancer biology,...
Epigenic Therapeutics Raises $60 Million to Advance CRISPR Epigenetic Therapies
China-based Epigenic Therapeutics secured $60 million in a Series B financing to expedite clinical development of gene therapy candidates EPI-003 for chronic hepatitis B and EPI-001 for...
Advances in AI Models Predicting Long-Term Cell Stability in Biotherapeutics
MIT researchers developed the first publicly accessible artificial intelligence model that predicts long-term stability of Chinese Hamster Ovary (CHO) cells used extensively in biotherapeutic...
RedC Biotech Develops Lab-Grown Universal Blood from Stem Cells
Israeli startup RedC Biotech pioneers production of universal red blood cells grown from stem cells in large bioreactors, aiming to alleviate global blood shortages responsible for approximately 2...
BioNTech and Bristol Myers Reveal Phase 2 PD-L1xVEGF Lung Cancer Results
BioNTech and Bristol Myers Squibb reported promising Phase 2 data for their bispecific antibody pumitamig (BNT327) targeting PD-1 and VEGF in extensive-stage small cell lung cancer (SCLC). The...
Summit Therapeutics Faces Setback in Global Lung Cancer Phase 3 Trial
Summit Therapeutics’ bispecific antibody ivonescimab failed to meet its primary overall survival endpoint in a global Phase 3 trial for non-small cell lung cancer (NSCLC), casting doubt on FDA...